T. Rowe Price Associates
CHRS icon

T. Rowe Price Associates’s Coherus Oncology CHRS Stock Holding History

T. Rowe Price Associates’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$121K Buy
71,536
+11,923
+20% +$21.2K ﹤0.01% 2954
2025
Q4 		$85K Hold
59,613
– – ﹤0.01% 2966
2025
Q3 		$98K Buy
59,613
+1,131
+2% +$1.26K ﹤0.01% 2929
2025
Q2 		$43K Buy
58,482
+10,329
+21% +$8.92K ﹤0.01% 3016
2025
Q1 		$39K Buy
48,153
+7,984
+20% +$9.19K ﹤0.01% 2957
2024
Q4 		$56K Hold
40,169
– – ﹤0.01% 2921
2024
Q3 		$42K Buy
40,169
+2,421
+6% +$3.32K ﹤0.01% 2950
2024
Q2 		$66K Buy
37,748
+6,897
+22% +$13.9K ﹤0.01% 2819
2024
Q1 		$74K Buy
30,851
+7,608
+33% +$18.7K ﹤0.01% 2826
2023
Q4 		$78K Buy
23,243
+1,116
+5% +$2.99K ﹤0.01% 2745
2023
Q3 		$83K Sell
22,127
-16,659
-43% -$76.9K ﹤0.01% 2695
2023
Q2 		$166K Buy
38,786
+1,444
+4% +$8.52K ﹤0.01% 2584
2023
Q1 		$256K Sell
37,342
-3,379
-8% -$26.2K ﹤0.01% 2421
2022
Q4 		$323K Sell
40,721
-15,055
-27% -$116K ﹤0.01% 2343
2022
Q3 		$537K Buy
55,776
+4,447
+9% +$45K ﹤0.01% 2082
2022
Q2 		$372K Buy
51,329
+12,995
+34% +$113K ﹤0.01% 2344
2022
Q1 		$495K Buy
38,334
+1,400
+4% +$17.8K ﹤0.01% 2343
2021
Q4 		$589K Sell
36,934
-1,144
-3% -$20K ﹤0.01% 2312
2021
Q3 		$612K Buy
38,078
+268
+0.7% +$3.93K ﹤0.01% 2282
2021
Q2 		$523K Buy
37,810
+1,284
+4% +$18.2K ﹤0.01% 2377
2021
Q1 		$534K Sell
36,526
-50,419
-58% -$856K ﹤0.01% 2337
2020
Q4 		$1.51M Sell
86,945
-210
-0.2% -$3.74K ﹤0.01% 1737
2020
Q3 		$1.6M Buy
87,155
+35,875
+70% +$667K ﹤0.01% 1621
2020
Q2 		$916K Sell
51,280
-13,874
-21% -$235K ﹤0.01% 1825
2020
Q1 		$1.06M Sell
65,154
-3,589
-5% -$66.3K ﹤0.01% 1678
2019
Q4 		$1.24M Buy
68,743
+2,493
+4% +$46K ﹤0.01% 1804
2019
Q3 		$1.34M Sell
66,250
-1,865
-3% -$37.3K ﹤0.01% 1691
2019
Q2 		$1.5M Sell
68,115
-426,104
-86% -$7.4M ﹤0.01% 1683
2019
Q1 		$6.74M Sell
494,219
-329,442
-40% -$4.4M ﹤0.01% 1367
2018
Q4 		$7.45M Sell
823,661
-449,658
-35% -$5.2M ﹤0.01% 1351
2018
Q3 		$21M Sell
1,273,319
-441,637
-26% -$7.83M ﹤0.01% 1218
2018
Q2 		$24M Buy
1,714,956
+222,857
+15% +$3.19M ﹤0.01% 1148
2018
Q1 		$16.5M Buy
1,492,099
+572,897
+62% +$6.27M ﹤0.01% 1245
2017
Q4 		$8.09M Sell
919,202
-292,270
-24% -$3.13M ﹤0.01% 1371
2017
Q3 		$16.2M Buy
1,211,472
+528,020
+77% +$6.98M ﹤0.01% 1248
2017
Q2 		$9.81M Sell
683,452
-122,894
-15% -$2.36M ﹤0.01% 1326
2017
Q1 		$17.1M Sell
806,346
-38,486
-5% -$947K ﹤0.01% 1222
2016
Q4 		$23.8M Buy
844,832
+13,510
+2% +$378K ﹤0.01% 1082
2016
Q3 		$22.3M Buy
+831,322
New +$22.7M ﹤0.01% 1096

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

T. Rowe Price Associates's CHRS Position: Q1 2026 in Review

T. Rowe Price Associates increased its Coherus Oncology (CHRS) stake by 20% in Q1 2026, buying an estimated $21.2K and bringing the position to 71,536 shares worth $121K. The position accounts for ﹤0.01% of the portfolio, ranked #2954.

T. Rowe Price Associates first reported a position in CHRS in Q3 2016 and has held it in 39 quarters since. The position peaked at $24M in Q2 2018. 157 funds tracked by Wall St. Rank hold CHRS as of Q1 2026.

  • T. Rowe Price Associates held 71,536 shares of Coherus Oncology worth $121K as of Q1 2026.
  • T. Rowe Price Associates bought 11,923 Coherus Oncology shares in Q1 2026, an estimated $21.2K.
  • Coherus Oncology made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #2954 holding.
  • T. Rowe Price Associates first reported a position in Coherus Oncology in Q3 2016 and has held it in 39 quarters since.
  • T. Rowe Price Associates's Coherus Oncology position peaked at $24M in Q2 2018.
  • 157 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.